Human immunodeficiency virus type 1 latency model for high-throughput screening

Antimicrob Agents Chemother. 2005 Dec;49(12):5185-8. doi: 10.1128/AAC.49.12.5185-5188.2005.

Abstract

Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Antiretroviral Therapy, Highly Active
  • HIV Infections / physiopathology*
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Models, Biological
  • Virus Latency / physiology*
  • Virus Replication / drug effects

Substances

  • Anti-HIV Agents